- Other Post Graduate Training - Stanford University (2006-2010)
- Fellowship - Johns Hopkins Hospitals & Health System (2002-2006), Medical Oncology
- Medical School - University of Rochester School of Medicine and Dentistry (1990-1999)
- Medical School - University of Rochester School of Medicine and Dentistry (1992-1997)
- Residency - University of Rochester/Strong Memorial Hospital (2000-2002), Internal Medicine
- Internship - University of Rochester/Strong Memorial Hospital (1999-2000), Internal Medicine
James Kim, M.D., Ph.D.
- Internal Medicine - Hematology/Oncology
- Lung Cancer
Biography
James Kim, M.D., Ph.D., is an Associate Professor in the Department of Internal Medicine at UT Southwestern Medical Center. He specializes in lung cancer and head and neck cancer.
A native of Seoul, South Korea, Dr. Kim earned his medical degree and doctoral degree in biophysical chemistry at the University of Rochester School of Medicine and Dentistry. He completed a residency in internal medicine at Strong Memorial Hospital in Rochester, New York, and received advanced training through an oncology fellowship at the Johns Hopkins Hospital and Health System. In addition, Dr. Kim completed a research fellowship at the Stanford University School of Medicine, where he studied the role of the Hedgehog signaling pathway in cancer development.
Certified by the American Board of Internal Medicine in medical oncology, he joined the UT Southwestern faculty in 2011.
At UT Southwestern, Dr. Kim serves on the UT Southwestern Tissue Repository (UTSTR) Oversight Committee, the UTSTR Subcommittee on Repository Database, and the Small Cell Lung Cancer Group.
He is a member of the American Association for Cancer Research, the American Society of Clinical Oncology, and the International Association for the Study of Lung Cancer. He serves as a charter member for the National Institutes of Health Advanced Therapeutics A study section. He also serves as an ad hoc reviewer for numerous journals, including the Journal of Biological Chemistry, Frontiers in Oncology, Oncogene, and Nature Communications.
Dr. Kim's laboratory focuses on how fundamental developmental pathways such as Hedgehog are involved in the initiation, growth, and metastases of cancers. The lab also seeks to understand the interactions of these pathways with each other and between tumor epithelia and stroma.
Dr. Kim has delivered numerous presentations and published several academic articles related to his areas of expertise.
Personal Note
When he’s not at work, Dr. Kim enjoys rock climbing, backpacking, sampling food and wine, and listening to music.
Education & Training
Professional Associations & Affiliations
- American Association for Cancer Research
- American Society of Clinical Oncology
- International Association for the Study of Lung Cancer
Honors & Awards
- Research Scholar Award 2016-2020, American Cancer Society
Books & Publications
-
Books
-
A method for orthotopic transplantation of lung cancer in mice in Hedgehog Signaling: Methods and Protocols
Wilson AN, Chen B, Liu X, Kurie JM, Kim J (2022), New York, NY, Humana
-
A method for orthotopic transplantation of lung cancer in mice in Hedgehog Signaling: Methods and Protocols
-
Publications
-
Posaconazole, a second-generation triazole antifungal drug, inhibits the Hedgehog signaling pathway and progression of basal cell carcinoma.
Chen B, Trang V, Lee A, Williams NS, Wilson AN, Epstein EH, Tang JY, Kim J Molecular cancer therapeutics 2016 Jan -
Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma.
Kim DJ, Kim J, Spaunhurst K, Montoya J, Khodosh R, Chandra K, Fu T, Gilliam A, Molgo M, Beachy PA, Tang JY Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014 Mar 32 8 745-51 -
Simultaneous measurement of smoothened entry into and exit from the primary cilium.
Kim J, Hsia EY, Kim J, Sever N, Beachy PA, Zheng X PloS one 2014 9 8 e104070 -
Hedgehog pathway modulation by multiple lipid binding sites on the smoothened effector of signal response.
Myers BR, Sever N, Chong YC, Kim J, Belani JD, Rychnovsky S, Bazan JF, Beachy PA Developmental cell 2013 Aug 26 4 346-57 -
Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists.
Kim J, Aftab BT, Tang JY, Kim D, Lee AH, Rezaee M, Kim J, Chen B, King EM, Borodovsky A, Riggins GJ, Epstein EH, Beachy PA, Rudin CM Cancer cell 2013 Jan 23 1 23-34 -
Hedgehog/Wnt feedback supports regenerative proliferation of epithelial stem cells in bladder
Shin K, lee J, Guo N, Kim J, Lim A, Qu L, Mysorekar IU, Beachy PA Nature 2011 Apr 7 472 (7341) 110-4 -
Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma
Monje M, Mitra SS, Freret ME, Raveh TB, Kim J, Masek M, Attema JL, Li G, Haddix T, Edwards MS, Fisher PG, Weissman IL, Rowitch DH, Vogel H, Wong AJ, Beachy PA Proceedings of the National Academy of Sciences 2011 Mar 15 108 (11) 4453-8 -
Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector
Kim J, Lee JJ, Kim J, Gardner D, Beachy PA Proceedings of the National Academy of Sciences 2010 Jul 27 107 (30) 13432-7 -
Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth
Kim J, Tang JY, Gong R, Kim J, Lee JJ, Clemons KV, Chong CR, Chang KS, Fereshteh M, Gardner D, Reya T, Liu JO, Epstein EH, Stevens DA, Beachy PA Cancer Cell 2010 Apr 13 17 (4) 388-99 -
Thermodynamics of coaxially stacked helixes with GA and CC mismatches
Kim J, Walter AE, Turner DH Biochemistry 1996 Oct 29 35 (43) 13753-61
-
Posaconazole, a second-generation triazole antifungal drug, inhibits the Hedgehog signaling pathway and progression of basal cell carcinoma.
Research
- Tumor epithelial-stromal interactions
- Molecularly targeted therapy
- Lung cancer
- Hedgehog signaling pathway
- Developmental pathways
Clinical Focus
- Lung Cancer